Gaush Meditech (2407) Fundamentals 2026 — P/E 6.9x, Revenue Analysis | SniperIQ
Gaush Meditech (2407) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK$776M, trading at HK$5.25 on the HKSE. This SniperIQ fundamentals page covers Gaush Meditech's valuation (P/E 6.9x, P/B 0.4x), profitability (net margin 7.0%), revenue (¥1.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Gaush Meditech's market cap?
Gaush Meditech (2407) has a market capitalization of approximately HK$776M, trading at HK$5.25 on the HKSE. Market cap moves with the live share price.
What is Gaush Meditech's P/E ratio?
Gaush Meditech's trailing twelve-month P/E ratio is 6.9x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Gaush Meditech?
Gaush Meditech runs a net profit margin of 7.0%, a gross margin of 45.9%, and an operating margin of 8.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Gaush Meditech generate?
Gaush Meditech reported revenue of ¥1.4B for fiscal year 2025, with net income of ¥96M and earnings per share (EPS) of 0.66. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Gaush Meditech pay a dividend?
Gaush Meditech offers a trailing dividend yield of about 5.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Gaush Meditech financially healthy?
Gaush Meditech carries a debt-to-equity ratio of 0.30x and a current ratio of 2.40x, with a market beta of 0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Gaush Meditech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Gaush Meditech (2407) the key facts are: market cap HK$776M, P/E 6.9x, revenue ¥1.4B, 52-week range 4.46-9.99. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Gaush Meditech's full fundamentals live
Get Gaush Meditech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.